Long-term Extension Study of Setrusumab in Adults With Type I, III, or IV Osteogenesis Imperfecta
Study sponsor: Ultragenyx Pharmaceutical Inc · RARE
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2022-07-07Actual
Enrollment · participants2Actual
Source updated2025-07-23Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.